> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves UCB Epilepsy Drug for Children
- URL: https://www.fdaweb.com/fda-approves-ucb-epilepsy-drug-for-children/
- Published: 2018-05-14T12:00:00.000Z
- Updated: 2026-09-15T00:04:56.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141431

FDA has approved a UCB supplemental NDA for Briviact (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in treating partial onset (focal) seizures in patients age four years and older. The expanded indication is based on extrapolation of efficacy data from adults to children, and is supported by safety and pharmacokinetic data collected in children. Pediatric epilepsy is the most common, serious neurological disorder among children and young adults, affecting nearly 470, 000 children in the U.S, the company says.